MDGL (Madrigal Pharmaceuticals) Accounts Payable: $35 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGL Madrigal Pharmaceuticals Inc MDGL
31 GF Score
Price $467.32
! 3 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Accounts Payable?

Madrigal Pharmaceuticals MDGL -5.23% 31 Accounts Payable is $35 Mil as of Jun. 2026. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Madrigal Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was $35 Mil.

Madrigal Pharmaceuticals's quarterly Accounts Payable increased from Dec. 2025 ($49 Mil) to Mar. 2026 ($61 Mil) but then declined from Mar. 2026 ($61 Mil) to Jun. 2026 ($35 Mil).

Madrigal Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 ($28 Mil) to Dec. 2024 ($44 Mil) and increased from Dec. 2024 ($44 Mil) to Dec. 2025 ($49 Mil).

Madrigal Pharmaceuticals Accounts Payable Related Terms

Madrigal Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals Accounts Payable Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.38 23.83 28.04 43.60 48.88

Madrigal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.98 44.94 48.88 60.80 34.51
MDGL
31GF Score
Madrigal Pharmaceuticals Inc MDGL
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $35 Mil mean?
Madrigal Pharmaceuticals (MDGL) has a Accounts Payable of $35 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' Accounts Payable too high?
Madrigal Pharmaceuticals' current Accounts Payable is $35 Mil. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Accounts Payable compare to AXSM and ARWR?
Madrigal Pharmaceuticals' Accounts Payable of $35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Accounts Payable is $35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current Accounts Payable of $35 Mil. The current Accounts Payable is $35 Mil. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current Accounts Payable is $35 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score

Get the complete analysis for MDGL

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$467.32
Price